20 results
A Controlled Trial of Erenumab for Episodic Migraine #EBM #Neuro #Erenumab #Migraine #CGRP #VisualAbstract #NEJM
Episodic Migraine #EBM ... Erenumab #Migraine #CGRP ... VisualAbstract #NEJM
An AAV5 vector with a functional factor VIII gene tested in men with hemophilia A #EBM
hemophilia A #EBM ... #Honc #hemophilia ... VisualAbstract #NEJM
Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer #EBM #Honc #Alectinib #Crizotinib #ALK #ALKPositive #NSCLC
Crizotinib in Untreated ALK-Positive ... Non–Small-Cell Lung Cancer #EBM ... #Honc #Alectinib ... #Crizotinib #ALK ... VisualAbstract #NEJM
Progression-free Survival  #EBM #Honc #Osimertinib #NSCLC #Survival #NEJM
Progression-free Survival #EBM ... #Honc #Osimertinib ... NSCLC #Survival #NEJM
Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind,
placebo-controlled pilot ... Devlin JW et al, ... CriticalCare #Delirium #EBM
Major Clinical Trials and Evidence Summary for Transfusion Thresholds in Critical Care

TRICC - NEJM 1999 -
Care TRICC - NEJM ... - ICU FOCUS - NEJM ... UGIB TRISS - NEJM ... ALI is the deadliest ... /vmoitra) #EBM
Pembrolizumab Response Rate by Tumor Type #EBM #Honc #Pharm #Pembrolizumab #Response #TumorType #Colorectal #Endometrial #Biliary #NEJM
by Tumor Type #EBM ... #Honc #Pharm #Pembrolizumab ... Endometrial #Biliary #NEJM
IgM and Non-IgM - Risk and Type of Progression #EBM #Honc #MGUS #Progression #IgM #NonIgM #MultipleMyeloma
of Progression #EBM ... #Honc #MGUS #Progression ... MultipleMyeloma #NEJM
Fremanezumab for the Preventive Treatment of Chronic Migraine - Primary and Secondary End Points #EBM #Neuro
Secondary End Points #EBM ... Fremanezumab #Migraine #CGRP ... CalcitoninGeneRelatedPeptideAntibody #Results #NEJM ... #NEJM
Cumulative Incidence of Progression of MGUS, with Death Accounted for as a Competing Risk #EBM #Honc
Competing Risk #EBM ... #Honc #MGUS #Progression ... #IgG #MGUS #NEJM